KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Receivables (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Change in Receivables for 16 consecutive years, with $138278.0 as the latest value for Q3 2025.

  • Quarterly Change in Receivables rose 55.24% to $138278.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$884149.0 through Sep 2025, down 214.13% year-over-year, with the annual reading at -$1.2 million for FY2024, 87.08% up from the prior year.
  • Change in Receivables hit $138278.0 in Q3 2025 for Inovio Pharmaceuticals, up from -$469925.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.9 million in Q2 2022 to a low of -$8.8 million in Q1 2021.
  • Historically, Change in Receivables has averaged -$951850.5 across 5 years, with a median of $81120.0 in 2023.
  • Biggest five-year swings in Change in Receivables: tumbled 14969.06% in 2021 and later soared 103.0% in 2024.
  • Year by year, Change in Receivables stood at $906955.0 in 2021, then soared by 82.76% to $1.7 million in 2022, then crashed by 84.25% to $261033.0 in 2023, then crashed by 354.25% to -$663683.0 in 2024, then surged by 120.83% to $138278.0 in 2025.
  • Business Quant data shows Change in Receivables for INO at $138278.0 in Q3 2025, -$469925.0 in Q2 2025, and $111181.0 in Q1 2025.